# Efficacy and Safety of Precision Therapy in Refractory Tumor

> **NCT03239015** · PHASE2 · UNKNOWN · sponsor: **Baodong Qin** · enrollment: 300 (estimated)

## Conditions studied

- Rare Tumor
- Refractory Tumor

## Interventions

- **DRUG:** Gefitinib
- **DRUG:** Erlotinib
- **DRUG:** Afatinib
- **DRUG:** Trastuzumab
- **DRUG:** Oxazolidine
- **DRUG:** Olaparib
- **DRUG:** Everolimus
- **DRUG:** Cabozantinib
- **DRUG:** Vemurafenib
- **DRUG:** Dabrafenib
- **DRUG:** Palbociclib
- **DRUG:** PD-1/L1 inhibitor plus anti-angiogenic agent

## Key facts

- **NCT ID:** NCT03239015
- **Lead sponsor:** Baodong Qin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-01-01
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-12-31
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2022-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03239015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03239015, "Efficacy and Safety of Precision Therapy in Refractory Tumor". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03239015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*